

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-10 (canceled)

Claim 11. (new) A method for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of

- (a) hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery;
 - (b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (MI), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, increase of formation of collagen, fibrosis, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; and
 - (c) endothelial dysfunction with or without hypertension;
- comprising administering to a warm-blooded animal, including man, a therapeutically effective amount of a pharmaceutical composition comprising an aldosterone synthase inhibitor in free or pharmaceutically acceptable salt form.

Claim 12. (new) The method of claim 12 wherein the aldosterone synthase inhibitor is selected from the group consisting of anastrozole, fadrozole, and exemestane, or, in each case where applicable, a pharmaceutically acceptable salt thereof.

Claim 13. (new) The method of claim 12 wherein the aldosterone synthase inhibitor is (+)-enantiomer of the hydrochloride of fadrozole of formula

